EdiGENE Appoints Naoki Kobayashi as Chief Financial Officer
Tokyo Japan and Cambridge, Mass. – March 28th, 2019 – EdiGENE, an emerging biotechnology company developing new CRISPR based therapies for treating genetic disorder, today announced that it is expanding its management team with the appointment of Mr. Naoki Kobayashi as its chief financial officer. Mr. Kobayashi’s most recent role was CFO and board member at Oncolys BioPharma Inc. (TSE Mothers: 4588), a specialty biotechnology company focused on oncology.
“Naoki brings his wide range of experience in the strategic financial management not only at biotech and healthcare companies but also at IT company throughout his experience of leading Hatena (TSE Mothers : 3930) to its successful IPO. He joins EdiGENE at a new stage of its growth with is expanded collaboration with pharmaceutical companies” said Haru Morita, EdiGENE’s president and chief executive officer. “Naoki’s depth of experience in capital raising strategy, operations, and finance complements the skills of our existing research team and matures operations focused on delivering novel gene therapies to people with genetic disorders.”
“EdiGENE has rapidly shaped an differentiated CRISPR based technology and assembled multiple alliances and collaborations for developing therapeutics with potential applicability across a broad variety of unmet genetic disorders,” said Naoki. “It is an exciting time for EdiGENE and I’m thrilled to be a part of the strong leadership team and to help accelerating the company’s development.”
Mr. Naoki joined Oncolys BioPharma in 2017 and oversaw financial, investor and administrative operations. Prior to Oncolys, he was CFO at Hatena, an internet services company with its the most popular social bookmarking service in Japan, Hatena Bookmark, At Hatena Naoki lead the company through its initial public offering and oversaw development from a privately-held to a publicly-traded commercial business. Previously, Naoki worked at Argens as CFO and member of the board. He played a critical role in operating its business and the sale of Argens to a pharmaceutical company. Before joining the biopharma industry, he worked as a consultant in the bio/pharma group at Deloitte Tohmatsu Consulting LLC to assists multiple biotech companies to establish corporate and financial strategy for their growth and was also a financial controller at Daikyo, a real-estate company. Naoki received a MBA from Hitotsubashi University in Tokyo Japan.
EdiGENE is an emerging biotech company that has been developing therapeutics with its proprietary technology named CRISR-GNDM. Our people, products, and partners believe “every life deserves attention” and try to develop therapeutics for genetic disorders mostly belong to orphan diseases. Follow us on Twitter and LinkedIn.